Infinity to Present at Two Upcoming Conferences

March 26, 2018 08:32

CAMBRIDGE, Mass., March 26, 2018 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing IPI-549, a potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), today announced that management will be presenting at the following two upcoming conferences:

Needham & Company Annual Healthcare Conference:Lawrence Bloch, M.D., J.D., Infinity's President, will present at Needham & Company's 17th Annual Healthcare Conference on Tuesday, March 27, 2018, at 11:00 a.m. ET at the Westin NY Grand Central Hotel in New York, NY. A live webcast of the presentation will be available on the Investors/Media section of Infinity's website at www.infi.com, and will be available for 30 days following the event.

8th Annual Cancer and Immunotherapy Conference: Jeffery Kutok, M.D., Ph.D., Infinity's Chief Scientific Officer, will present during the "The Tumor Microenvironment in Cancer: Reevaluating Checkpoints on Suppressive Myeloid Cells," session at the 8th Annual Cancer and Immunotherapy Conference hosted by William Blair & Company and MaidStone Life Sciences on April 5, 2018, at 10:40 a.m. ET at the Apella Event Space Alexandria Center, New York, NY. 

About Infinity
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. A Phase 1/1b study in approximately 200 patients with advanced solid tumors is ongoing. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Contact:
Stephanie Ascher, Stern Investor Relations, Inc.
212-362-1200 or Stephanie@sternir.com

Cision View original content:http://www.prnewswire.com/news-releases/infinity-to-present-at-two-upcoming-conferences-300619141.html

SOURCE Infinity Pharmaceuticals, Inc.

Related Stories

Biotech bankruptcies hit a record despite sector’s recovery
SA Breaking News 03/14 14:54 ET
INFI MONDAY DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 16 Deadline in Securities Class Action – INFI
Globe Newswire 10/13 16:45 ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Infinity Pharmaceuticals, Inc. - INFI
Globe Newswire 10/11 11:21 ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 16 Deadline in Securities Class Action – INFI
Globe Newswire 10/03 15:36 ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Infinity Pharmaceuticals, Inc. - INFI
Globe Newswire 10/03 12:28 ET
DEADLINE ALERT for KEY, LYV, APLD, and INFI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
Globe Newswire 10/03 12:07 ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Accesswire 10/03 04:30 ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Applied Digital, Infinity, and Shift4 and Encourages Investors to Contact the Firm
Globe Newswire 10/02 21:00 ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $500,000 to Contact the Firm
Accesswire 10/01 23:45 ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Infinity Pharmaceuticals, Inc. - INFI
PR Newswire 09/29 17:22 ET